Speaking from the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, William Wierda, MD, PhD, from The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the end of Phase I results of the ZUMA-3 study (NCT02614066) for axicabtagene ciloleucel in relapsed/refractory adult acute lymphoblastic leukemia (ALL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

свернуть